In the latest National Institute on Aging and Alzheimer's Association (NIA-AA) Research Framework criteria (2018), AD has been re-defined based on the underlying pathology (amyloid pathology/A, tau pathology/T and neurodegeneration/N) that can be documented in vivo by biomarkers or by post-mortem examination (147). This evidence concerns the gene MAPT and amyloidosis.